Pharma in Focus - knowledge in power
8 - 14 Mar 2010
 
Analysis: HTA changes, more bureaucracy or faster to market?
By July this year the pharmaceutical industry may be facing a new layer of bureaucracy in making market approval reimbursement submissions but there is also hope those submissions will move faster
R&D trend means a challenging trials environment
This week the trend for major pharma companies to re-examine their commitment to R&D came into sharp focus again as AstraZeneca announced where it would implement R&D cuts revealed in general terms some weeks before
Subscribe to Pharma in Focus

Sign Up Now

What you'll pay

A two week trial of Pharma in Focus is FREE of charge.

Paid subscription to Pharma in Focus costs $339.95 per year. This can be substantially reduced if you qualify for our LOYALTY BONUS*

3 Simple Steps

Fill in your details below and submit
Make your subscription choice*
Make your payment choice (Visa, MasterCard, Invoice)

*LOYALTY BONUS:
If your organisation already has paid-up subscribers, we offer a substantial loyalty bonus on additional subscriptions. Our system will check when you enter your details below.

Email Address
Retype your Email Address
First Name
Last name
Company or Organisation
Position
Phone
Send me News Alerts as
 HTML (colourful) OR Text only
 

Note: When your subscription has expired we hope you will renew it but we will continue to send you the weekly Pharma in Focus News Alert whether you renew or not. You can unsubscribe from this service at any time.

Access: Full text access is immediate.

Privacy policy: The list on which your email address appears is protected and will not be sold or passed on to any other organisation or individual.

TOP | BACK

 
 
Instant Update: Thurs 11 March
..full report
Vioxx claims in hundreds of millions
..full report
Generic fines well below MA levels
..full report
PBAC's last fee-free meeting
..full report
Amgen, Hospira in patent wrangle
..full report
Backlog distorts PBS statistics
..full report
Combos stopped osteo drug decline
..full report
Reckitt fights back on Nurofen Plus
..full report
IT bungle delays PI, CMI capture
..full report
© 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus